Alzamend Neuro, Inc. (ALZN)
Oxford Ledge is still expanding full research coverage of ALZN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Alzamend Neuro develops novel lithium-based and cell-based therapeutics for Alzheimer's disease and psychiatric disorders through clinical-stage trials.
SEC filings
- 8-K Shareholder vote results; Financial statements and exhibits 2026-04-17
- 8-K Delisting / transfer of listing; Financial statements and exhibits 2026-03-20
- 10-Q Quarterly financial report (unaudited) 2026-03-11
- 8-K Entry into material agreement; Financial statements and exhibits 2026-03-06
- DEF 14A Proxy statement for shareholder vote 2026-02-26
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ALZN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ALZN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.